Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 16Sarcoma 5Lymphoid 2Breast 2Tumor-Agnostic 1Genitourinary 1CNS 1

Conditions

Fallopian Tube Mucinous Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 63Specimen Handling 58pembrolizumab 40enzalutamide 38Nivolumab 32Gemcitabine 30Docetaxel 28Biopsy 25Prednisone 23Abiraterone Acetate 21apalutamide 20Androgen Antagonists 19Radiosurgery 18Cisplatin 18darolutamide 16cabozantinib 16abiraterone 16Radiotherapy 16enfortumab vedotin 15Radiation 14Ipilimumab 13belzutifan 12Pluvicto 12Mitomycin 12olaparib 11erdafitinib 11durvalumab 11atezolizumab 11X-Rays 10Standard of Care 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
liposomal doxorubicin × Genitourinary × 30 days × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡